Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 6
1978 3
1979 5
1980 7
1981 9
1982 19
1983 14
1984 14
1985 10
1986 18
1987 23
1988 19
1989 12
1990 13
1991 12
1992 21
1993 25
1994 33
1995 20
1996 28
1997 30
1998 30
1999 18
2000 25
2001 19
2002 25
2003 29
2004 24
2005 38
2006 39
2007 51
2008 47
2009 35
2010 53
2011 68
2012 79
2013 83
2014 65
2015 72
2016 61
2017 51
2018 51
2019 39
2020 41
2021 54
2022 57
2023 53
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,406 results

Results by year

Filters applied: . Clear all
Page 1
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S. Lofwall MR, et al. JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052. JAMA Intern Med. 2018. PMID: 29799968 Free PMC article. Clinical Trial.
IMPORTANCE: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. OBJECTIVE: To determine whether treatment involving novel weekly and monthly subcutaneous (SC) buprenorphine depot formulations is noninferior to a daily s …
IMPORTANCE: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. OBJECTIVE: To determin …
Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners' offices in Malaysia: a randomized, open-label clinical trial.
Schottenfeld RS, Chawarski MC, Mazlan M. Schottenfeld RS, et al. Addiction. 2021 Aug;116(8):2135-2149. doi: 10.1111/add.15399. Epub 2021 Jan 21. Addiction. 2021. PMID: 33404150 Clinical Trial.
This study aimed to evaluate two behavioral interventions to improve buprenorphine-naloxone treatment. DESIGN: A 2 2 factorial, repeated-measures, open-label, randomized clinical trial. ...CONCLUSIONS: Providing opioid-dependent patients in Muar, Malaysia with buprenorp …
This study aimed to evaluate two behavioral interventions to improve buprenorphine-naloxone treatment. DESIGN: A 2 2 factorial, repea …
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Arunogiri S, Hayes V, Hjelmström P, Svedberg A, Peterson S, Tiberg F. Lintzeris N, et al. JAMA Netw Open. 2021 May 3;4(5):e219041. doi: 10.1001/jamanetworkopen.2021.9041. JAMA Netw Open. 2021. PMID: 33970256 Free PMC article. Clinical Trial.
IMPORTANCE: Patient-reported outcomes in the treatment of opioid dependence may differ between subcutaneously administered depot buprenorphine and daily sublingual buprenorphine. OBJECTIVE: To compare patient satisfaction between depot buprenorphine and subli …
IMPORTANCE: Patient-reported outcomes in the treatment of opioid dependence may differ between subcutaneously administered depot buprenor …
Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Hser YI, et al. Addiction. 2022 Jan;117(1):151-161. doi: 10.1111/add.15594. Epub 2021 Jun 22. Addiction. 2022. PMID: 34105213 Free PMC article. Clinical Trial.
AIMS: To investigate whether reduction in opioid use differs when treated by either buprenorphine-naloxone (BUP) or methadone (MET) among adults with comorbid opioid use disorder (OUD) and mental disorders. ...CONCLUSIONS: Among adults with comorbid opioid use disorder and …
AIMS: To investigate whether reduction in opioid use differs when treated by either buprenorphine-naloxone (BUP) or methadone (MET) a …
A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.
Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE, Fitzgerald TT, Vocci FJ. Gordon MS, et al. Drug Alcohol Depend. 2017 Mar 1;172:34-42. doi: 10.1016/j.drugalcdep.2016.11.037. Epub 2017 Jan 11. Drug Alcohol Depend. 2017. PMID: 28107680 Free PMC article. Clinical Trial.
METHODS: Study design was a 2 (In-Prison Treatment: Condition: Buprenorphine Treatment: vs. Counseling Only)2 [Post-Release Service Setting Condition: Opioid Treatment: Program (OTP) vs. ...RESULTS: Participants (N=211) in the in-prison treatment condition effect had a hig …
METHODS: Study design was a 2 (In-Prison Treatment: Condition: Buprenorphine Treatment: vs. Counseling Only)2 [Post-Release Service S …
Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial.
Ahmadpanah M, Reihani A, Ghaleiha A, Soltanian A, Haghighi M, Jahangard L, Sadeghi Bahmani D, Holsboer-Trachsler E, Brand S. Ahmadpanah M, et al. J Psychiatr Res. 2017 Nov;94:23-28. doi: 10.1016/j.jpsychires.2017.06.004. Epub 2017 Jun 13. J Psychiatr Res. 2017. PMID: 28647677 Clinical Trial.
Buprenorphine (2-4 mg; sublingual) and placebo (tablets with identical shape, color, consistency, and scent) were given daily. ...Adjuvant buprenorphine seems to accelerate symptom improvement....
Buprenorphine (2-4 mg; sublingual) and placebo (tablets with identical shape, color, consistency, and scent) were given daily. ...Adj …
The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, Ehrlich ME, Kraft WK. Moore JN, et al. Clin Pharmacol Ther. 2018 Jun;103(6):1029-1037. doi: 10.1002/cpt.1064. Epub 2018 Apr 28. Clin Pharmacol Ther. 2018. PMID: 29516490 Free PMC article. Clinical Trial.
In a randomized, controlled trial assessing the efficacy of buprenorphine and morphine in NAS, blood samples were analyzed from a subset of patients receiving buprenorphine along with NAS scores. ...The findings confirm a previous PK model of buprenorphine an …
In a randomized, controlled trial assessing the efficacy of buprenorphine and morphine in NAS, blood samples were analyzed from a sub …
The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.
D'Onofrio G, Hawk KF, Herring AA, Perrone J, Cowan E, McCormack RP, Dziura J, Taylor RA, Coupet E, Edelman EJ, Pantalon MV, Owens PH, Martel SH, O'Connor PG, Van Veldhuisen P, DeVogel N, Huntley K, Murphy SM, Lofwall MR, Walsh SL, Fiellin DA. D'Onofrio G, et al. Contemp Clin Trials. 2021 May;104:106359. doi: 10.1016/j.cct.2021.106359. Epub 2021 Mar 16. Contemp Clin Trials. 2021. PMID: 33737199 Free PMC article. Clinical Trial.
ED-INNOVATION (Emergency Department-INitiated bupreNOrphine VAlidaTION) is a Hybrid Type-1 Implementation-Effectiveness multisite emergency department (ED) study funded through The Helping to End Addiction Long-term(SM) Initiative, or NIH HEAL Initiative(SM) efforts to inc …
ED-INNOVATION (Emergency Department-INitiated bupreNOrphine VAlidaTION) is a Hybrid Type-1 Implementation-Effectiveness multisite eme …
Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.
Hassan AN, Bozinoff N, Jutras-Aswad D, Socias ME, Stewart SH, Lim R, Le Foll B; OPTIMA Research Group. Hassan AN, et al. J Addict Med. 2023 Jan-Feb 01;17(1):e49-e56. doi: 10.1097/ADM.0000000000001048. Epub 2022 Aug 2. J Addict Med. 2023. PMID: 35916430 Free PMC article. Clinical Trial.
The effectiveness of standard methadone model of care was compared with flexible take-home buprenorphine/naloxone dispensation model of care in patients with prescription-type OUD. ...There was no significant difference in CSQ based on treatment assignment (methadone vs fl …
The effectiveness of standard methadone model of care was compared with flexible take-home buprenorphine/naloxone dispensation model …
Physicians' satisfaction with providing buprenorphine treatment.
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Collier E, Starr S, Madden LM, Haram E, Toy A, Molfenter T. Knudsen HK, et al. Addict Sci Clin Pract. 2019 Aug 26;14(1):34. doi: 10.1186/s13722-019-0163-3. Addict Sci Clin Pract. 2019. PMID: 31446893 Free PMC article. Clinical Trial.
BACKGROUND: Buprenorphine is a critically important treatment for addressing the opioid epidemic, but there are virtually no studies of physicians' job satisfaction with providing buprenorphine. ...Study measures included global job satisfaction, career satisfaction …
BACKGROUND: Buprenorphine is a critically important treatment for addressing the opioid epidemic, but there are virtually no studies …
1,406 results